VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Storka, Angela ^a   Burian, Bernhard ^a   Führlinger, Gerhard ^b   Clive, Breanna ^a   Sun, Terri ^a   Crevenna, Richard ^a   Gsur, Andrea ^b   Mosgöller, Wilhelm ^b   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADULT; ARTICLE; CELL POPULATION; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INNATE IMMUNITY; LEUKOCYTE; LYMPHOCYTE; MALE; MONOCYTE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; VOLUNTEER;

ADOLESCENT; ADULT; CELL SEPARATION; ENDOTOXEMIA; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GRANULOCYTES; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TIME FACTORS; YOUNG ADULT;

EID: 84877023524     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-117     Document Type: Article

References (37)

1. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970, 169(951):1217-1218. 10.1126/science.169.3951.1217, 5450698.
2. Mutt V, Said SI. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur J Biochem 1974, 42(2):581-589. 10.1111/j.1432-1033.1974.tb03373.x, 4829446.
3. Morice A, Unwin RJ, Sever PS. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 1983, 2(8361):1225-1227.
4. Huang M, Shirahase H, Rorstad OP. Comparative study of vascular relaxation and receptor binding by PACAP and VIP. Peptides 1993, 14(4):755-762. 10.1016/0196-9781(93)90109-T, 8234021.
5. Offen D, et al. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 2000, 854(1-2):257-262.
6. Brenneman DE, et al. Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. Ann N Y Acad Sci 1997, 814:167-173. 10.1111/j.1749-6632.1997.tb46155.x, 9160969.
7. Edwards AV, Bloom SR, Ghatei MA. Pancreatic endocrine responses to the peptides VIP and PACAP in the conscious calf. Exp Physiol 1997, 82(4):717-727.
8. Kawai K, et al. Pituitary adenylate cyclase activating polypeptide stimulates insulin release from the isolated perfused rat pancreas. Life Sci 1992, 50(4):257-261. 10.1016/0024-3205(92)90332-J, 1732697.
9. Delgado M, et al. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci 2000, 921:68-78.
10. Gomariz R, et al. Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia. Ann N Y Acad Sci 2000, 921:284-288.
11. Leceta J, et al. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci 2000, 921:92-102.
12. Delgado M, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol 1999, 162(4):2358-2367.
13. Martinez C, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol 1998, 63(5):591-601.
14. Delgado M, et al. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 1999, 96(2):167-181. 10.1016/S0165-5728(99)00023-5, 10337915.
15. Delgado M, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999, 162(8):4685-4696.
16. Delgado M, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999, 162(3):1707-1716.
17. Sreedharan SP, et al. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 1993, 193(2):546-553. 10.1006/bbrc.1993.1658, 8390245.
18. Lutz EM, et al. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993, 334(1):3-8. 10.1016/0014-5793(93)81668-P, 8224221.
19. Svoboda M, et al. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994, 205(3):1617-1624. 10.1006/bbrc.1994.2852, 7811244.
20. Ogi K, et al. Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. Biochem Biophys Res Commun 1993, 196(3):1511-1521. 10.1006/bbrc.1993.2423, 7902709.
21. Delgado M, et al. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 2000, 30(11):3236-3246. 10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L, 11093139.
22. Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008, 172(5):1297-1307. 10.2353/ajpath.2008.070969, 2329838, 18385521.
23. Tuncel N, Tore FC. The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide synthase on survival rate in rats exposed to endotoxin shock. Ann N Y Acad Sci 1998, 865:586-589. 10.1111/j.1749-6632.1998.tb11241.x, 9928074.
24. Delgado M, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 1999, 162(2):1200-1205.
25. Cobo M, et al. Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. Cell Transplant 2012, Epub ahead of print.
26. Delgado M, et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001, 7(5):563-568. 10.1038/87887, 11329057.
27. Langlet C, et al. Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling. J Biol Chem 2005, 280(30):28034-28043. 10.1074/jbc.M500449200, 15932876.
28. Baggiolini M, et al. Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst. FASEB J 1993, 7(11):1004-1010.
29. Crane MJ, Hokeness-Antonelli KL, Salazar-Mather TP. Regulation of inflammatory monocyte/macrophage recruitment from the bone marrow during murine cytomegalovirus infection: role for type I interferons in localized induction of CCR2 ligands. J Immunol 2009, 183(4):2810-2817. 10.4049/jimmunol.0900205, 2911023, 19620305.
30. Teng L, et al. Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection. Mol Cell Biochem 2012, 360(1-2):271-277. 10.1007/s11010-011-1066-0, 21964536.
31. Burian B, et al. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides 2010, 31(4):603-608. 10.1016/j.peptides.2009.12.014, 20026142.
32. Ortner A, et al. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target 2010, 18(6):457-467. 10.3109/10611860903508796, 20050817.
33. Brandtzaeg P, et al. Elevated VIP and endotoxin plasma levels in human gram-negative septic shock. Regul Pept 1989, 24(1):37-44. 10.1016/0167-0115(89)90209-7, 2500680.
34. Petkov V, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003, 111(9):1339-1346. 154449, 12727925.
35. Lara-Marquez M, et al. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2001, 166(4):2522-2530.
36. Finney SJ, et al. Differences in lipopolysaccharide- and lipoteichoic acid-induced cytokine/chemokine expression. Intensive Care Med 2012, 38(2):324-332. 10.1007/s00134-011-2444-5, 3264860, 22183712.
37. Munford RS, Andersen JM, Dietschy JM. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest 1981, 68(6):1503-1513. 10.1172/JCI110404, 370954, 7033286.